Department of Biotechnology and BIRAC Host 14th Webinar
The Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC) hosted the 14th webinar in their series focused on biomanufacturing and biofoundry initiatives on May 16, 2025. This session centered on “Biomanufacturing for mRNA Therapeutics,” a crucial aspect of the BioE3 Policy, which aims to establish India as a leader in bio-based innovations. The policy, approved by the Union Cabinet, seeks to promote sustainable biomanufacturing across various sectors, including precision therapeutics, thereby enhancing economic growth and ensuring affordable healthcare for the Indian populace.
Insights from the DBT Leadership
Dr. Alka Sharma, a senior adviser at DBT, emphasized the BioE3 Policy’s commitment to advancing high-performance biomanufacturing while promoting sustainable growth. She noted that this initiative represents a significant global shift towards sustainability, potentially leading to a “BioRevolution” that could transform economies and societies. Dr. Sharma highlighted the focus on mRNA therapeutics, a key area under the policy, and pointed out that numerous Indian biotech firms and research institutions are actively working on mRNA-based vaccines and therapies. However, she also acknowledged challenges such as product delivery, stability, and reliance on imported raw materials that need to be addressed for the sector to thrive.
Advancements in mRNA Therapeutics
Dr. Varshneya Singh, a scientist at DBT, provided a comprehensive overview of the mRNA therapeutics sector, describing it as a groundbreaking advancement in biotechnology. He explained that mRNA therapies have the potential to address a wide range of diseases, including cancer and infectious diseases. Dr. Singh conducted a SWOT analysis of the subsector, identifying its strengths, weaknesses, opportunities, and threats. He concluded by announcing a new Call for Proposals for Precision Biotherapeutics-mRNA Therapeutics, a collaborative effort by DBT and BIRAC aimed at fostering innovation and scaling up developments in this promising field.
Innovations in mRNA Vaccine Technology
Dr. Raghavan Varadarajan from IISc Bangalore discussed the latest advancements in mRNA-LNP vaccine technology, highlighting its transformative role in modern medicine. He elaborated on the mRNA vaccine design process, the advantages of mRNA technology, and the key structural elements of mRNA. Additionally, Dr. Varadarajan provided insights into the workflow for lipid nanoparticle (LNP) preparation, comparing various mRNA-LNP formulations and the microfluidic chips used in their production. His presentation underscored the importance of these innovations in enhancing vaccine efficacy and delivery.
Challenges and Opportunities in RNA Therapeutics
Dr. Monalisa Chatterji from Sekkei Bio Pvt. Ltd. addressed critical issues surrounding the limited adoption of biologics and the potential of RNA therapeutics. She pointed out the significant opportunities available for fully realizing the benefits of these advanced therapies. Dr. Chatterji stressed the necessity of expanding manufacturing capabilities and the need for substantial capital investment to support the growth and implementation of RNA technologies. The session concluded with an engaging Q&A segment, where participants discussed the challenges and opportunities in biomanufacturing, as well as regulatory considerations, fostering a collaborative atmosphere among experts and attendees.
Observer Voice is the one stop site for National, International news, Sports, Editorโs Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
Follow Us on Twitter, Instagram, Facebook, & LinkedIn
